Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humana Part D Cost-Sharing For Tier 3 Drugs Up Sharply In 2009

Executive Summary

Humana's nationally available stand-alone Medicare prescription drug plans will require significantly higher cost sharing for non-preferred and specialty drug coverage in 2009

You may also be interested in...



Part D Trends In 2009: Higher Premiums, Reduced Gap Coverage

Premium increases among all stand-alone Medicare Part D plans will average 24 percent in 2009, led by price hikes of 60 percent or more by Humana, according to an analysis of CMS data by Avalere Health

Humana Bows Out Of Medicare Part D Coverage For Dual Eligibles

In 2009, Humana will complete its exit from providing Medicare Part D benefits to low-income seniors who qualify for both Medicaid and Medicare coverage

Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs

The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel